Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Poolbeg PharmaPOLBF EV-to-OCF is -7.41 as of Jul. 28, 2026. The stock has 1 warning sign investors should review. Among 1,407 Biotechnology companies, Poolbeg Pharma ranks better than 64.96% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Poolbeg Pharma's Enterprise Value is $47.60 Mil.
Poolbeg Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.42 Mil. Therefore, Poolbeg Pharma's EV-to-OCF for today is -7.41.
The historical rank and industry rank for Poolbeg Pharma's EV-to-OCF or its related term are showing as below:
POLBF'
s EV-to-OCF Range Over the Past 10 Years
Min: -7.49 Med: 0 Max: -7.49
Current: -7.49
During the past 5 years, the highest EV-to-OCF of Poolbeg Pharma was -7.49. The lowest was -7.49. And the median was .
POLBF's EV-to-OCF is ranked better than 64.96% of 1407
companies
in the Biotechnology industry
Industry Median: -3.28
vs POLBF: -7.49
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Poolbeg Pharma's PE Ratio (TTM) for today is calculated as:
Poolbeg Pharma's share price for today is $0.095.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Poolbeg Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.013.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Poolbeg Pharma EV-to-OCF Related Terms
Poolbeg Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Poolbeg Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's EV-to-OCF falls into.
Poolbeg Pharma's current Enterprise Value is $47.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Poolbeg Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poolbeg Pharma (POLBF) has a EV-to-OCF of -7.41 as of Jul. 28, 2026. According to the industry distribution chart, Poolbeg Pharma ranks #493 out of 1407 companies in the Biotechnology industry, placing it in the top 35%.
Is Poolbeg Pharma's EV-to-OCF too high?
Poolbeg Pharma's current EV-to-OCF is -7.41. Based on the distribution chart, Poolbeg Pharma ranks #493 out of 1407 companies in the Biotechnology industry, which is above the industry midpoint.
How does Poolbeg Pharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #493 out of 1407 companies for EV-to-OCF. This puts Poolbeg Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Poolbeg Pharma's current EV-to-OCF is -7.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current EV-to-OCF of -7.41. The current EV-to-OCF is -7.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current EV-to-OCF is -7.41 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 
